
Baxter International company profile
$25.81+0.27%Close 13 Nov 2026 · Market value $13.30B
About Baxter International
Baxter International Inc. provides healthcare products through its subsidiaries, including sterile intravenous solutions, infusion systems, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, surgical hemostat and sealant products, smart bed systems, patient monitoring and diagnostic technologies, and respiratory health devices. Its products are used by hospitals, nursing homes, ambulatory surgery centers, doctors' offices, kidney dialysis centers and patients at home under physician supervision. Baxter reports three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. Sales are made directly and through independent distributors, sales agents and specialty pharmacies in more than 100 countries, and products are manufactured in over 20 countries.
A summary of the business section of the company's latest annual report, filed 12 Feb 2026.
Company facts
| Ticker | BAX · NYSE |
|---|
| Sector | Medical devices |
|---|
| Industry | Health Care Equipment |
|---|
| Index | S&P 500 |
|---|
| Fiscal year ends | 31 December |
|---|
| Reporting currency | USD |
|---|
| CIK | 10456 |
|---|
| Latest annual report | 10-K, filed 12 Feb 2026 |
|---|
Officers and directors
| Name | Role | Shares owned | Latest Form 4 |
|---|
| Hider Andrew P. | President and CEO · Director | — | Shares withheld for tax, 2 Sep 2026 |
|---|
| Foster Julie | President, Front Line Care | — | Shares withheld for tax, 2 Sep 2026 |
|---|
| Teaff James | President, CCS | — | Shares withheld for tax, 1 Sep 2026 |
|---|
| Wallace Steven P. | President, Adv. Surgery | — | Shares withheld for tax, 2 Jun 2026 |
|---|
| Zielinski Anita A | SVP, Interim CFO, CAO & Cntrlr | — | Grant or award, 1 Jun 2026 |
|---|
| Wilkes David S. | Director | — | Grant or award, 5 May 2026 |
|---|
| Wendell Amy McBride | Director | — | Grant or award, 5 May 2026 |
|---|
| SCHLICHTING NANCY M | Director | — | Grant or award, 5 May 2026 |
|---|
| MORRISON PATRICIA | Director | — | Grant or award, 5 May 2026 |
|---|
| Shafer David Brent | Director · Chair of the Board | — | Grant or award, 5 May 2026 |
|---|
| McDonnell Michael R. | Director | — | Grant or award, 5 May 2026 |
|---|
| Craig Jeffrey A | Director | — | Grant or award, 5 May 2026 |
|---|
| Ampofo William A. II | Director | — | Grant or award, 5 May 2026 |
|---|
| Soriano Maria Cecilia | Group Pres., ITT & Pharma. | — | Shares withheld for tax, 6 Mar 2026 |
|---|
| Rosenbloom David S. | EVP and General Counsel | — | Shares withheld for tax, 6 Mar 2026 |
|---|
| Rasul Reazur | EVP,Group Pres,Healthcare | — | Shares withheld for tax, 6 Mar 2026 |
|---|
| Grade Joel T. | EVP and CFO | — | Shares withheld for tax, 6 Mar 2026 |
|---|
| Carlisle Cynthia | Executive Vice President, CHRO | — | Grant or award, 27 Feb 2026 |
|---|
| Mason Jeanne K | EVP, Chief HR Officer | — | Shares withheld for tax, 12 Dec 2025 |
|---|
| Sonig Alok | EVP,Group President,Pharma | — | Shares withheld for tax, 2 Sep 2025 |
|---|
Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.
BAX in the terminal
The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.